ENLIVEN THERAPEUTICS, INC. Operating Leases, Rent Expense
ENLIVEN THERAPEUTICS, INC. (ELVN) reported Operating Leases, Rent Expense of $81.00 thousand for the 3-month period ending 2024-03-31, per its 10-Q filed 2024-05-14.
Discontinued › Expense Statement › Operating Expenses
us-gaap:LeaseAndRentalExpense · last filed 2024-05-14
- ENLIVEN THERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2024-03-31 was $81.00K, a 0.00% change year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2023-12-31 was $56.00K, a 51.35% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2023-09-30 was $81.00K, a 0.00% change year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating leases, rent expense for the quarter ending 2023-06-30 was $82.00K, a 100.00% increase year-over-year.
- ENLIVEN THERAPEUTICS, INC. operating leases, rent expense for fiscal 2023 was $300.00K, a 50.00% increase from fiscal 2022.
- ENLIVEN THERAPEUTICS, INC. operating leases, rent expense for fiscal 2022 was $200.00K.
| Period end | Operating Leases, Rent Expense 1 month | Operating Leases, Rent Expense 3 month | Operating Leases, Rent Expense 6 month | Operating Leases, Rent Expense 9 month | Operating Leases, Rent Expense 12 month |
|---|---|---|---|---|---|
| 2024-03-31 | $81.00K 10-Q · filed 2024-05-14 | $137.00K derived: sum of 2 quarters · filed 2024-05-14 | $218.00K derived: sum of 3 quarters · filed 2024-05-14 | $300.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-12-31 | $56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $137.00K derived: sum of 2 quarters · filed 2024-03-14 | $219.00K derived: sum of 3 quarters · filed 2024-03-14 | $300.00K 10-K · filed 2024-03-14 | |
| 2023-09-30 | $81.00K 10-Q · filed 2023-11-09 | $163.00K derived: sum of 2 quarters · filed 2023-11-09 | $244.00K 10-Q · filed 2023-11-09 | $281.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-06-30 | $82.00K 10-Q · filed 2023-08-10 | $163.00K 10-Q · filed 2023-08-10 | $200.00K derived: sum of 3 quarters · filed 2024-05-14 | $281.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2023-03-31 | $81.00K 10-Q · filed 2024-05-14 | $118.00K derived: sum of 2 quarters · filed 2024-05-14 | $199.00K derived: sum of 3 quarters · filed 2024-05-14 | $240.00K derived: sum of 4 quarters · filed 2024-05-14 | |
| 2022-12-31 | $37.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $118.00K derived: sum of 2 quarters · filed 2024-03-14 | $159.00K derived: sum of 3 quarters · filed 2024-03-14 | $200.00K 10-K · filed 2024-03-14 | |
| 2022-09-30 | $81.00K 10-Q · filed 2023-11-09 | $122.00K derived: sum of 2 quarters · filed 2023-11-09 | $163.00K 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $41.00K 10-Q · filed 2023-08-10 | $82.00K 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $41.00K 10-Q · filed 2023-05-11 | ||||
| 2021-12-31 | $200.00K 8-K · filed 2023-06-23 | ||||
| 2021-03-31 | $12.00K 10-Q · filed 2024-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 |